46.46 0.00 (0.00%)
After hours: 5:04PM EDT
|Bid||46.51 x 1800|
|Ask||46.52 x 1000|
|Day's Range||46.05 - 47.37|
|52 Week Range||33.51 - 67.85|
|Beta (3Y Monthly)||2.19|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
SAN FRANCISCO, June 28, 2019 -- FibroGen, Inc. (NASDAQ: FGEN), today announced that the company will present interim data on their open-label, single-arm Phase 2 trial.
SAN FRANCISCO, June 10, 2019 -- FibroGen, Inc. (NASDAQ: FGEN), a leading biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics, today.
“Suzanne Blaug joins the FibroGen Board of Directors at a key time for the company. “I am excited to join FibroGen's Board as the company prepares for critical next steps in the regulatory and commercial development of roxadustat for the treatment of anemia associated with CKD and in other important applications in the treatment of anemia.
NEW YORK, NY / ACCESSWIRE / May 15, 2019 / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against FibroGen, Inc. ("FibroGen" or the "Company") ...
Positive topline results from pooled safety analyses of roxadustat Phase 3 global programCompleted one year of treatment in Phase 2 trial evaluating pamrevlumab in treatment of.
FibroGen, Inc. (FGEN) today announced topline results from the pooled safety analyses of the global Phase 3 program for roxadustat, an inhibitor of hypoxia-inducible-factor (HIF) prolyl hydroxylase activity (HIF-PHI). The global pivotal Phase 3 trials were conducted by FibroGen and collaboration partners AstraZeneca and Astellas Pharma, Inc., for treatment of anemia in chronic kidney disease (CKD) patients across the non-dialysis-dependent (NDD), incident (newly initiated) dialysis, and dialysis-dependent (DD) CKD populations, enrolled from more than 50 countries.
SAN FRANCISCO, May 06, 2019 -- FibroGen, Inc. (NASDAQ: FGEN) today announced that it will report first quarter 2019 financial results on Thursday, May 9, 2019 after market.
“We are pleased to have received Orphan Drug Designation from the FDA for pamrevlumab in the treatment of DMD. There is high unmet medical need for patients suffering from this debilitating disease needing a new treatment option,” said Elias Kouchakji, M.D., Senior Vice President, Clinical Development and Drug Safety. “All 21 non-ambulatory DMD patients in our ongoing phase 2 study with pamrevlumab have completed the first 52 weeks of treatment.
—Roxadustat Approved in China for Anemia in Dialysis-Dependent CKD Patients— —Primary Efficacy Endpoints Met in Seven Phase 3 Roxadustat Studies for U.S./EU—.
NEW YORK, NY / ACCESSWIRE / January 17, 2019 / Despite concerns of a partial government shutdown, U.S. markets extended gains for the second consecutive session on Wednesday on strong earnings from Bank ...
NEW YORK, Jan. 17, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
FibroGen, Inc. (FGEN), a leading biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics, today announced that roxadustat, an inhibitor of hypoxia-inducible-factor (HIF) prolyl hydroxylase activity (HIF-PHI), met all primary efficacy endpoints in the three global pivotal Phase 3 trials conducted by FibroGen: ANDES in non-dialysis-dependent (NDD) chronic kidney disease (CKD) patients, HIMALAYAS in incident (newly initiated) dialysis patients, and SIERRAS in dialysis-dependent (DD) CKD patients. “Anemia in CKD is a serious condition for which a significant number of patients are left without treatment options in many markets,” said Thomas B. Neff, Chief Executive Officer, FibroGen.
NEW YORK, NY / ACCESSWIRE / December 20, 2018 / U.S. equities closed down on Wednesday as the anticipated interest rate increase was confirmed by the Federal Reserve, following Chairman Jerome Powell’s ...
NEW YORK, NY / ACCESSWIRE / December 18, 2018 / U.S. equities extended losses on Monday as investors await details from the Federal Reserve's final policy meeting of 2018 on Wednesday. The Dow Jones Industrial ...
FibroGen, Inc. (FGEN) today announced that FibroGen (China) Medical Technology Development Co., Ltd. (FibroGen China) has received marketing authorization from the National Medical Products Administration (NMPA) for roxadustat, a first-in-class hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) for the treatment of patients with anemia caused by chronic kidney disease (CKD) in patients who are dialysis-dependent (DD). The medicine can be prescribed to patients who use hemodialysis or peritoneal dialysis.
“We are delighted to welcome Dr. Maykin Ho, an accomplished leader with a great breadth of knowledge in the biotechnology industry, as a new Board member,” said Thomas B. Neff, CEO. Dr. Ho has more than 30 years of experience in the healthcare and finance industries.
NEW YORK, Nov. 27, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
NEW YORK, NY / ACCESSWIRE / November 14, 2018 / U.S. equities saw losses on Tuesday as continued weakness in oil prices pressured energy stocks lower. Crude oil dropped for the 12th consecutive session, ...
—Roxadustat New Drug Applications under Review in China and Japan——Phase 3 Clinical Trials in IPF and Pancreatic Cancer to Initiate in First Quarter 2019——Conference Call Today.
Conference Call and Audio Webcast Scheduled for 5:00 p.m. ET (2:00 p.m. PT) SAN FRANCISCO, Nov. 02, 2018 -- FibroGen, Inc. (NASDAQ: FGEN), a biopharmaceutical company, today.
TOKYO and SAN FRANCISCO, Oct. 30, 2018 -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and FibroGen, Inc. (Nasdaq: FGEN, CEO: Thomas.
NEW YORK, NY / ACCESSWIRE / October 18, 2018 / Major U.S. equities finished moderately lower on Wednesday with the Dow Jones dropping over 300 points after minutes from the Federal Reserve September’s ...